How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

550 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

421. Shingles

. [ ] The antivirals that are used are (adult dose): [ ] Aciclovir 800 mg five times a day for seven days (continuing until two days after crusting of lesions in those who are immunocompromised). Valaciclovir 1000 mg three times a day for seven days; or Famciclovir 500 mg three times a day for seven days (or ten days in immunocompromised individuals) or 750 mg once or twice a day for seven days. One review found a significant reduction in risk of pain with valaciclovir and famciclovir for management of herpes (...) zoster virus (HZV) including ophthalmicus. Valaciclovir or famciclovir were both shown to provide significant reduction in the risk of HZV-associated pain. [ ] An oral antiviral drug should be started within 72 hours of rash onset for: Anyone over the age of 50 years. People of any age with non-truncal involvement (eg, affecting the neck, limbs or perineum). Cases where there is moderate or severe pain or rash. Those with ophthalmic involvement. People who are immunocompromised. If it is not possible

2008 Mentor

422. Chemoprophylaxis in HIV

to all individuals living with HIV, especially those with a CD count below 200/mm 3 . Secondary prevention CMV - use ganciclovir to prevent retinitis. Long-acting drug-release intravitreous implants have been shown to be cost-effective. Herpes simplex - may require temporary daily suppressive treatment with oral aciclovir. There are limited safety data for famciclovir and valaciclovir. Oral candidiasis - may require suppressive treatment with an antifungal agent. Salmonella - long-term therapy may

2008 Mentor

423. Bacterial Conjunctivitis

antiviral treatment as soon as the diagnosis is made (eg, aciclovir, valaciclovir or famciclovir) . Refer for ophthalmic review. The eye and surrounding structures may also be affected and slit-lamp examination is needed to exclude corneal involvement or developing uveitis, scleritis, retinitis, neuritis and cranial nerve palsies. Possible sequelae include scarring and glaucoma. Molluscum contagiosum conjunctivitis [ ] This oncogenic virus generally infects the skin but occasionally spreads to mucous

2008 Mentor

424. Human Immunodeficiency Virus

to all individuals living with HIV, especially those with a CD count below 200/mm 3 . Secondary prevention CMV - use ganciclovir to prevent retinitis. Long-acting drug-release intravitreous implants have been shown to be cost-effective. Herpes simplex - may require temporary daily suppressive treatment with oral aciclovir. There are limited safety data for famciclovir and valaciclovir. Oral candidiasis - may require suppressive treatment with an antifungal agent. Salmonella - long-term therapy may

2008 Mentor

425. Herpes Simplex Genital

of infection usually causes less severe symptoms, which are more rapidly self-limiting. Options for management are: Supportive measures alone (as described above). Antiviral therapy as required (episodic treatment). Suppressive therapy. Episodic antiviral treatment Oral aciclovir, valaciclovir, and famciclovir have all been shown to reduce duration (by a median of 1-2 days) and severity of episodes of genital herpes. No advantage has been shown of one therapy over another. Short-course therapy has been (...) found to be equally effective as five-day treatment. The earlier the treatment is started, the more effective it is likely to be. Therefore, people with recurrent genital herpes should have a course pre-prescribed so they can start it as soon as they feel the earliest symptoms developing. BASHH advises the following short courses as options for first-line therapy: Aciclovir 800 mg three times daily for two days. Famciclovir 1 g twice daily for one day. Valaciclovir 500 mg twice daily for three days

2008 Mentor

426. Herpes Simplex Eye Infections

provide some symptomatic relief. Antibacterial ointment may prevent secondary infection of the lesions but its use is not widespread. Use of antiviral ointment is equivocal with conflicting evidence as to its efficacy in reducing keratitis. Epithelial keratitis - topical antiviral treatment is the norm - eg, aciclovir five times a day until at least three days after complete healing. Alternatives include famciclovir or oral antivirals (which have the benefit of not being toxic to the corneal

2008 Mentor

427. External Eye - Lashes Eyelids and Lacrimal System

occurs in the older patient population. The eyelid, conjunctiva, episclera, sclera, cornea and anterior chamber may all be involved. (Cutaneous involvement of the tip of the nose suggests an increased likelihood of ocular complications, as this area is served by the first division of the nerve: this is called Hutchinson's sign.) Treatment is with systemic antivirals (eg, famciclovir 750 mg od for 7-10 days). Management of the lid involves cool compresses and topical lubrication (topical antibiotics

2008 Mentor

428. Genital Herpes in Pregnancy

, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010 Aug 25304(8):859-66. ; Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev. 2008 Jan 23(1):CD004946. ; Herpes simplex virus infection in pregnancy. Infect Dis Obstet Gynecol. 20122012:385697. Epub 2012 Apr 11. ; Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis

2008 Mentor

429. [Expensive long-term care with virustatic drugs frequently reduces herpes genitalis episodes]. (Abstract)

-Episoden. Switzerland Praxis (Bern 1994) 101468093 1661-8157 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir IM 2-Aminopurine administration & dosage analogs & derivatives economics Adult Antiviral Agents administration & dosage economics Cost-Benefit Analysis Double-Blind Method Drug Costs Famciclovir Female Herpes Genitalis drug therapy economics Humans Long-Term Care economics Male Recurrence 1999 7 27 1999 7 27 0 1 1999 7 27 0 0 ppublish 10420805

1999 Praxis Controlled trial quality: uncertain

430. Percutaneous electrical nerve stimulation: an alternative to antiviral drugs for acute herpes zoster. (Abstract)

Ghoname E S ES Hamza M A MA Gajraj N M NM Taylor S M SM eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Anesth Analg 1310650 0003-2999 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir AIM IM Anesth Analg. 1999 Dec;89(6):1585-6 10589658 2-Aminopurine analogs & derivatives therapeutic use Acute Disease Adult Antiviral Agents therapeutic use Famciclovir Female Herpes Zoster therapy Humans Male Middle Aged Pain Management Pain

1998 Anesthesia and Analgesia Controlled trial quality: uncertain

431. Famvir effective in suppressing recurrent genital herpes. (Abstract)

Famvir effective in suppressing recurrent genital herpes. 11362073 1999 04 01 2018 12 01 1087-2914 12 12 1998 Dec AIDS patient care and STDs AIDS Patient Care STDS Famvir effective in suppressing recurrent genital herpes. 944 eng Clinical Trial Multicenter Study News Randomized Controlled Trial United States AIDS Patient Care STDS 9607225 1087-2914 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir X 2-Aminopurine analogs & derivatives therapeutic use Antiviral Agents therapeutic (...) use Double-Blind Method Famciclovir Female Herpes Simplex drug therapy prevention & control Humans Male Recurrence 2001 5 22 10 0 2001 5 22 10 1 2001 5 22 10 0 ppublish 11362073

1999 AIDS patient care and STDs Controlled trial quality: uncertain

432. Management of herpes simplex and varicella-zoster virus infections. (Full text)

agents, famciclovir and valacyclovir hydrochloride, have been approved for the short-term treatment of recurrent genital herpes simplex virus and recurrent zoster in nonimmunocompromised hosts. Famciclovir and valacyclovir demonstrate superior pharmacokinetics compared with acyclovir and allow for less frequent daily dosing with higher achievable serum drug concentrations. The attenuated live varicella virus vaccine is now available in the United States and prevents primary varicella-zoster virus

1997 Western Journal of Medicine PubMed abstract

433. Translating Statistics for Use in the Clinic (Full text)

Translating Statistics for Use in the Clinic 9346459 1997 11 21 2018 12 01 0884-8734 12 10 1997 Oct Journal of general internal medicine J Gen Intern Med Translating statistics for use in the clinic. 626-8 Atkins C D CD eng Case Reports Journal Article United States J Gen Intern Med 8605834 0884-8734 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir IM 2-Aminopurine analogs & derivatives therapeutic use Antiviral Agents therapeutic use Breast Neoplasms epidemiology prevention (...) & control Clinical Trials as Topic methods Data Interpretation, Statistical Famciclovir Female Herpes Zoster diagnosis drug therapy Humans Male Mammography Middle Aged Models, Statistical Patient Education as Topic Sensitivity and Specificity 1997 11 5 1997 11 5 0 1 1997 11 5 0 0 ppublish 9346459 PMC1497176

1997 Journal of General Internal Medicine PubMed abstract

434. Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice (Full text)

Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice Acyclovir (ACV) resistant herpes simplex virus (HSV) isolates can be readily selected in animal infection models receiving suboptimal ACV treatment, however no comparative studies of the emergence of resistance following suboptimal treatment with valacyclovir (VCV) or famciclovir (FCV), the prodrugs of acyclovir and penciclovir, respectively, have been reported.Mice

2001 BMC infectious diseases PubMed abstract

435. Phenotypic and Genetic Characterization of Thymidine Kinase from Clinical Strains of Varicella-Zoster Virus Resistant to Acyclovir (Full text)

Phenotypic and Genetic Characterization of Thymidine Kinase from Clinical Strains of Varicella-Zoster Virus Resistant to Acyclovir Varicella-zoster virus (VZV) is a common herpesvirus responsible for disseminated or chronic infections in immunocompromised patients. Effective drugs such as acyclovir (ACV), famciclovir (prodrug of penciclovir), and foscarnet are available to treat these infections. Here we report the phenotypic and genetic characterization of four ACV-resistant VZV strains

1999 Antimicrobial Agents and Chemotherapy PubMed abstract

436. Persistence of Infectious Herpes Simplex Virus Type 2 in the Nervous System in Mice after Antiviral Chemotherapy (Full text)

Persistence of Infectious Herpes Simplex Virus Type 2 in the Nervous System in Mice after Antiviral Chemotherapy Young adult mice were inoculated with herpes simplex virus type 2 (HSV-2) in the ear pinna. A relatively severe infection resulted, and 45% of the mice died by 11 days postinfection. Therapy at 1 mg/ml by means of the drinking water with either famciclovir for periods of 5 or 10 days or valaciclovir for 5, 10, 15, or 20 days decreased clinical signs and reduced mortality to 15 (...) % or less. Throughout a period of 27 days, mice were tested daily for the presence of infectious virus in the ear pinna, brain stem, and ipsilateral trigeminal ganglia. Virus was cleared from these tissues in surviving, untreated animals by 12 days postinfection, and no infectious virus was detected subsequently in any tissue. Furthermore, no infectious virus was detected after day 9 in mice that had been treated with famciclovir. In mice that had received valaciclovir therapy, however, infectious virus

2000 Antimicrobial Agents and Chemotherapy PubMed abstract

437. Graded challenge in an aciclovir allergic patient (Full text)

Graded challenge in an aciclovir allergic patient An immunocompetent woman presented with a hypersensitivity skin reaction following suppressive therapy with aciclovir for recurrent culture proved genital herpes simplex virus infection. She developed a similar reaction when treatment was changed to famciclovir. Without antiviral suppression her recurrences were frequent and distressing. Graded challenge was performed and she became tolerant to aciclovir. She successfully continued suppressive

2001 Sexually transmitted infections PubMed abstract

438. Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy (Full text)

Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy Since the introduction of antiviral compounds such as lamivudine and famciclovir in the treatment schedules of patients with chronic hepatitis B virus (HBV) infection, the accumulation of a variety of mutations in the HBV polymerase gene has been observed. The selection of these mutations is generally considered the cause of viral nonresponsiveness and treatment failure. Therefore

2000 Journal of clinical microbiology PubMed abstract

439. A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

anti-HSV therapy, which is defined as therapy of 12 or more weeks.) Agree to use effective methods of birth control from 2 weeks before taking study drug, throughout the study, and for 4 weeks after completing the study. (A female may be eligible if not able to have children.) Exclusion Criteria Patients will not be eligible for this study if they: Have blood vessel disease. Are sensitive to acyclovir, Valtrex, famciclovir, or ganciclovir. Are unable to take medications by mouth. Have non-healed (...) to acyclovir, Valtrex, famciclovir, or ganciclovir. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005663 Sponsors and Collaborators Glaxo Wellcome More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Other Study

2000 Clinical Trials

440. Valaciclovir to Prevent Transmission of Herpes Simplex Virus

transaminase (ALT) level greater than 3 times the normal upper limit. Known resistance to aciclovir, famciclovir, or ganciclovir. Known hypersensitivity to aciclovir, valaciclovir, famciclovir, or ganciclovir. Malabsorption syndrome or other gastrointestinal dysfunction that might impair drug dynamics. Subjects known to be lactose intolerant. Women contemplating pregnancy within the duration of study drug dosing for this study. Women of child bearing potential not using an effective method of contraception

1999 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>